Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 8/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 11/20 | 0.40 |
| ▸ | DRD1 | P21728 | 3/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271564 | 0.98 | HRH3 (0.41) | HRH3DRD2HTR1ADRD1DRD5 | |
| SCHEMBL22129196 | 0.88 | HRH3 (0.51) | HRH3DRD2HTR1ADRD1 | |
| SCHEMBL8493200 | 0.79 | MEN1 (0.42) | DRD2HTR1ADRD1DRD5DRD3 | |
| SCHEMBL8496611 | 0.79 | DRD2 (0.40) | DRD2HTR1ADRD1DRD5DRD3 | |
| SCHEMBL12656140 | 0.79 | NOTUM (0.51) | HRH3DRD2 | |
| SCHEMBL8496898 | 0.79 | HTR1A (0.38) | DRD2HTR1A | |
| SCHEMBL13228227 | 0.77 | NOTUM (0.53) | HRH3DRD2DRD3 | |
| SCHEMBL26890101 | 0.77 | DRD2 (0.41) | HRH3DRD2HTR1ADRD3 | |
| SCHEMBL22129231 | 0.77 | DRD2 (0.49) | DRD2HTR1ADRD1 | |
| SCHEMBL8497315 | 0.77 | ALDH1A1 (0.40) | DRD2HTR1ADRD1DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | L'OREAL (FR) | 2004-11-25 | — | — | US | claimed |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | L'OREAL (FR) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | KRT18, CDC73, PYCR1 | HTR1A 1965/4885HRH3 99/4885DRD2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.